KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Exchange Rate Effect (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Exchange Rate Effect for 4 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect rose 160.11% year-over-year to $2.1 million, compared with a TTM value of $18.0 million through Dec 2025, up 629.77%, and an annual FY2025 reading of $18.0 million, up 629.77% over the prior year.
  • Exchange Rate Effect was $2.1 million for Q4 2025 at Recursion Pharmaceuticals, up from $1.9 million in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $9.3 million in Q2 2025 and bottomed at -$3.5 million in Q4 2024.
  • Average Exchange Rate Effect over 4 years is $1.1 million, with a median of $124000.0 recorded in 2023.
  • The sharpest move saw Exchange Rate Effect plummeted 10850.0% in 2024, then soared 7943.22% in 2025.
  • Year by year, Exchange Rate Effect stood at -$307000.0 in 2022, then skyrocketed by 140.39% to $124000.0 in 2023, then tumbled by 2900.0% to -$3.5 million in 2024, then soared by 160.11% to $2.1 million in 2025.
  • Business Quant data shows Exchange Rate Effect for RXRX at $2.1 million in Q4 2025, $1.9 million in Q3 2025, and $9.3 million in Q2 2025.